Developer docs
API playgroundTry for free, no card

Search company profiles

Miravo

Full company profile

uuid0025sm4

Namestring
Miravo
Legal namestring
Searchlight Pharma Inc.
Company typeenum
Private
Founded yearint
1983
Short descriptiontext

Miravo is a Canadian healthcare company that produces therapeutic and natural healthcare products across pain, allergy, neurology, and dermatology indications, operating a portfolio of 65+ brands as the specialty pharmaceutical division of Apotex.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMississauga, Canada
HQ citystring
Mississauga
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
specialty pharmaceuticals, therapeutic products, women's health, pain management, dermatology products
Product category
Specialty Pharmaceuticals
No data
Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Commercial Brands
Description

Products marketed by Searchlight Pharma in Canada.

searchlightpharma.com
+2 more records
Core offering1 text field

Miravo is a healthcare company that develops, acquires, and commercializes specialty pharmaceutical and natural healthcare products across therapeutic areas including pain, allergy, neurology, and dermatology. The company markets a portfolio of over 65 brands through direct commercial operations in Canada and through strategic partners in international markets.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Commercial Brands Portfolio
CategorySpecialty Pharmaceuticals
Description

A portfolio of branded specialty pharmaceutical and healthcare products marketed by Searchlight Pharma in Canada, covering women's health, dermatology, allergy, neurology, pain management, and hospital specialty markets. Targeted at healthcare providers and patients through Canadian distribution.

2Partnered Brands Portfolio
CategorySpecialty Pharmaceuticals
Description

A network of strategic partners who have introduced Searchlight Pharma products to patients in new markets across the globe. Focused on global commercialization of specialty pharmaceutical products.

3Pharmaceutical Pipeline Products
CategorySpecialty Pharmaceuticals
Description

Innovative pharmaceutical products in development across various therapeutic areas, intended to expand the company's branded specialty pharmaceutical offerings.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Miravo's parent company and one of Canada's largest generic, biosimilar, and branded pharmaceutical producers — comparable as the broader enterprise of which Miravo is the specialty pharma division, and a key strategic/operational counterparty.

TypeDirect peer
Description

Canadian specialty pharmaceutical company commercializing branded products in dermatology and other specialty areas — directly comparable in therapeutic focus and commercial scale.

TypeDirect peer
Description

Canadian specialty pharma commercializing branded products across women's health, dermatology, and specialty categories — directly comparable therapeutic-area overlap with Miravo.

4Acerus Pharmaceuticals
TypeDirect peer
Description

Canadian specialty pharma commercializing products in men's health, women's health, and specialty therapeutics — comparable niche branded-pharma model and Canadian geographic focus.

5Endo International (Paladin Labs)
TypeBroad incumbent
Description

Global specialty pharma that historically operated Paladin Labs in Canada as a specialty branded distribution platform — directly comparable Canadian specialty pharma distribution and commercialization model.

TypeDirect peer
Description

Canadian specialty pharmaceutical company that commercializes innovative and branded products across multiple therapeutic areas in Canada and select international markets — directly comparable business model to Miravo's branded specialty pharma model.

TypeDirect peer
Description

Canadian specialty pharma focused on acquiring and commercializing branded products in CNS, cardiovascular, and specialty categories — closely mirrors Miravo's specialty-brand acquisition and commercialization model.

TypeEmerging player
Description

India-headquartered specialty pharma with branded portfolios in dermatology, respiratory, and pain — comparable in therapeutic focus and emerging-market distribution model relevant to Miravo's partnered-brand strategy.

TypeBroad incumbent
Description

Large Canadian-headquartered specialty pharma with diversified branded portfolios across dermatology, neurology, and women's health — broader and larger-scale competitor operating in several of Miravo's therapeutic areas.

TypeDirect peer
Description

Canadian specialty biopharma focused on specialty therapeutics with commercial reach in North America and select global markets — comparable branded specialty pharma positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Miravo

Specialty Pharmaceuticalsmiravohealthcare.com

Miravo is a Canadian healthcare company that produces therapeutic and natural healthcare products across pain, allergy, neurology, and dermatology indications, operating a portfolio of 65+ brands as the specialty pharmaceutical division of Apotex.

Miravo firmographics

Firmographics
Name
Miravo
Legal name
Searchlight Pharma Inc.
Website
https://miravohealthcare.com
Company type
Private
Founded year
1983
Operating status
Operating
Headcount range
51–100 employees
Short description
Miravo is a Canadian healthcare company that produces therapeutic and natural healthcare products across pain, allergy, neurology, and dermatology indications, operating a portfolio of 65+ brands as the specialty pharmaceutical division of Apotex.
Ownership category
akta.pro rank

Where Miravo is headquartered

Location

Headquarters

HQ city
Mississauga
HQ country
Canada
HQ region
North America

Markets served

Miravo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Miravo product offering

Product offering

Core offering

Miravo is a healthcare company that develops, acquires, and commercializes specialty pharmaceutical and natural healthcare products across therapeutic areas including pain, allergy, neurology, and dermatology. The company markets a portfolio of over 65 brands through direct commercial operations in Canada and through strategic partners in international markets.

Differentiator

Problem solved

Functional benefit

Brands

  • Commercial Brands: Products marketed by Searchlight Pharma in Canada.
  • Partnered Brands
  • Pipeline

Products and services

  • Commercial Brands Portfolio A portfolio of branded specialty pharmaceutical and healthcare products marketed by Searchlight Pharma in Canada, covering women's health, dermatology, allergy, neurology, pain management, and hospital specialty markets. Targeted at healthcare providers and patients through Canadian distribution.
  • Partnered Brands Portfolio A network of strategic partners who have introduced Searchlight Pharma products to patients in new markets across the globe. Focused on global commercialization of specialty pharmaceutical products.
  • Pharmaceutical Pipeline Products Innovative pharmaceutical products in development across various therapeutic areas, intended to expand the company's branded specialty pharmaceutical offerings.

Companies that use Miravo

Customer profile

Ideal customer profiles2 records

Miravo technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Miravo partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Miravo competitors and assessment

Company assessment

Others

  • Apotex Inc. Miravo's parent company and one of Canada's largest generic, biosimilar, and branded pharmaceutical producers — comparable as the broader enterprise of which Miravo is the specialty pharma division, and a key strategic/operational counterparty.

Direct peers

  • Cipher Pharmaceuticals: Canadian specialty pharmaceutical company commercializing branded products in dermatology and other specialty areas — directly comparable in therapeutic focus and commercial scale.
  • Verity Pharmaceuticals: Canadian specialty pharma commercializing branded products across women's health, dermatology, and specialty categories — directly comparable therapeutic-area overlap with Miravo.
  • Acerus Pharmaceuticals: Canadian specialty pharma commercializing products in men's health, women's health, and specialty therapeutics — comparable niche branded-pharma model and Canadian geographic focus.
  • Knight Therapeutics: Canadian specialty pharmaceutical company that commercializes innovative and branded products across multiple therapeutic areas in Canada and select international markets — directly comparable business model to Miravo's branded specialty pharma model.
  • HLS Therapeutics: Canadian specialty pharma focused on acquiring and commercializing branded products in CNS, cardiovascular, and specialty categories — closely mirrors Miravo's specialty-brand acquisition and commercialization model.
  • Theratechnologies: Canadian specialty biopharma focused on specialty therapeutics with commercial reach in North America and select global markets — comparable branded specialty pharma positioning.

Broad incumbents

  • Endo International (Paladin Labs): Global specialty pharma that historically operated Paladin Labs in Canada as a specialty branded distribution platform — directly comparable Canadian specialty pharma distribution and commercialization model.
  • Bausch Health: Large Canadian-headquartered specialty pharma with diversified branded portfolios across dermatology, neurology, and women's health — broader and larger-scale competitor operating in several of Miravo's therapeutic areas.

Emerging players

  • Glenmark Pharmaceuticals: India-headquartered specialty pharma with branded portfolios in dermatology, respiratory, and pain — comparable in therapeutic focus and emerging-market distribution model relevant to Miravo's partnered-brand strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Miravo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Miravo leadership team

Management profile

Number of profiles

Profiles3 records

Miravo funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Miravo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Miravo

What does Miravo do?

Miravo is a healthcare company that develops, acquires, and commercializes specialty pharmaceutical and natural healthcare products across therapeutic areas including pain, allergy, neurology, and dermatology. The company markets a portfolio of over 65 brands through direct commercial operations in Canada and through strategic partners in international markets.

Is Miravo a public or private company?

Miravo is a private company. It is classified as corporate owned and is currently operating.

When was Miravo founded?

Miravo was founded in 1983. It employs 51 to 100 people.

Where is Miravo based?

Miravo is headquartered in Mississauga, Canada, in the North America region.

Who are Miravo's main competitors?

Apotex Inc. is listed as an others. Direct peers are Cipher Pharmaceuticals, Verity Pharmaceuticals, Acerus Pharmaceuticals, Knight Therapeutics, HLS Therapeutics and Theratechnologies. Broad incumbents are Endo International (Paladin Labs) and Bausch Health. Glenmark Pharmaceuticals is listed as an emerging player.

Does Miravo have an API?

No public API is recorded for Miravo.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldReviewing CannTrust (OTCMKTS:CNTTF) & Nuvo Pharmaceuticals (OTCMKTS:MRVFF)This article presents a comparative analysis of CannTrust Holdings Inc. and Nuvo Pharmaceuticals Inc., two Canadian pharmaceutical companies, examining metrics including revenue, earnings, valuation ratios, volatility, and profitability. CannTrust shows higher earnings ($7.39 million vs -$25.70 million) but lower revenue ($15.96 million vs $54.98 million), while Nuvo Pharmaceuticals trades at a lower price-to-earnings ratio and demonstrates lower stock volatility (beta of 0.98 vs 4.52). The analysis concludes that CannTrust outperforms Nuvo Pharmaceuticals on 6 of 10 factors compared between the two stocks.BioSpaceMiravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to its Board of DirectorsMiravo Healthcare appointed Dale MacCandlish Weil to its Board of Directors during its May 16, 2022 annual general meeting. Weil, currently executive director of a palliative care residence, brings healthcare industry experience from McKesson Canada and other roles. The appointment aims to add insights as the company executes its strategy.PR NewswireViscosupplementation Devices Market Is Growing At a CAGR Of 7.93% During The Forecast Period From 2021 To 2026 And Will Touch USD 6 Billion By 2026, Affirms DelveInsightDelveInsight published a market research report projecting the global viscosupplementation devices market to grow at a CAGR of 7.93% from 2021 to 2026, reaching USD 6 billion by 2026. The report highlights recent product launches including Seikagaku's Hylink single-injection viscosupplement in Taiwan and Nuvo Pharmaceuticals' NeoVisc+ products in Canada. North America is expected to lead the market due to high arthritis prevalence, favorable reimbursement policies, and established healthcare infrastructure, while COVID-19 temporarily reduced demand for elective procedures.PR NewswireMiravo Healthcare™ Announces Participation at the H.C. Wainwright 23rd Annual Global Investment ConferenceNuvo Pharmaceuticals Inc. (operating as Miravo Healthcare), a Canadian-focused healthcare company, announced it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled as a virtual event on September 13-15, 2021. Company President & CEO Jesse Ledger and VP & CFO Mary-Jane Burkett will provide an overview of the business to institutional and retail investors during the presentation.PR NewswireMiravo Healthcare™ Announces Second Quarter 2021 ResultsNuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare) reported Q2 2021 adjusted total revenue of $19.9 million, an 11% increase year-over-year, driven by a 46% rise in revenue from its promoted products Blexten and Cambia, though adjusted EBITDA declined 3% to $7.4 million. The company repaid $3.0 million of its Amortization Loan to Deerfield Management and entered an exclusive license agreement with SK Chemicals to commercialize Suvexx in South Korea for up to €1.1 million in upfront and milestone payments. For the six-month period, adjusted total revenue decreased 7% to $34.5 million due to generic competition impacting Vimovo royalties in the United States.PR NewswireMiravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South KoreaMiravo Healthcare announced that its subsidiary Miravo Ireland has entered into an exclusive license and supply agreement with SK Chemicals Co., Ltd. for the commercialization of Suvexx, an acute migraine treatment, in South Korea. Under the terms of the agreement, SK Chemicals will receive exclusive rights to commercialize Suvexx in South Korea, with an anticipated commercial launch in 2023 pending regulatory approval, which would entitle Suvexx to up to 6 years of marketing exclusivity in the territory. Miravo Ireland will receive up to EUR 1.1 million in upfront consideration, regulatory and sales-based milestone payments, as well as royalties on net sales and revenue from product supply.PR NewswireMiravo Healthcare™ to Present at Access to Giving Virtual Investor ConferenceNuvo Pharmaceuticals Inc., operating as Miravo Healthcare, has been invited to present at the Access to Giving Virtual Investor Conference scheduled for July 13-15, 2021. The company's President and CEO Jesse Ledger along with CFO Mary-Jane Burkett will deliver presentations aimed at investor education and advocacy. This event serves as a platform for the healthcare company to engage with qualified investors regarding its commercial product portfolio.PR NewswireMiravo Healthcare™ to Present at Summer Solstice - Best Ideas from the Buy SideNuvo Pharmaceuticals Inc., operating as Miravo Healthcare, has been invited to present at the MicroCap Rodeo Summer Solstice Best Ideas Conference, a virtual event scheduled for June 1-4, 2021. President and CEO Jesse Ledger and Vice President and CFO Mary-Jane Burkett will represent the company, with management available for one-on-one investor meetings throughout the conference. The Canadian healthcare company, which maintains its head office in Mississauga, Ontario and a manufacturing facility in Varennes, Quebec, was selected as one of 35 top investment ideas by qualified institutional investors.PR NewswireMiravo Healthcare™ Announces Appointment of Mary Ritchie to its Board of DirectorsNuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare) announced the appointment of Mary Ritchie to its Board of Directors during the company's Annual General Meeting of Shareholders on May 17, 2021. Ritchie, who currently serves as President and CEO of Richford Holdings Ltd., brings over 30 years of experience across public, private, and not-for-profit sectors and previously served on boards including the Canada Pension Plan Investment Board and Axcan Pharma Inc. CEO Jesse Ledger stated that Ritchie's cross-sector experience and audit committee background make her an valuable addition to the board.PR NewswireMiravo Healthcare™ Announces Director Election Results of its Annual Meeting of ShareholdersMiravo Healthcare (d/b/a Nuvo Pharmaceuticals) held its 2021 Virtual Annual Meeting of Shareholders on May 17, 2021, where all six nominated directors were elected with approval rates ranging from 91.55% to 97.68%. The company also announced the reappointment of Ernst & Young LLP as its auditors for the ensuing fiscal year. This was a routine annual corporate governance event with no material surprises or strategic implications disclosed.